# Incyte

> Incyte is a global biopharmaceutical company developing and commercializing prescription medicines for blood disorders, cancers, inflammation and autoimmunity. Its ruxolitinib franchise spans oral Jakafi and topical Opzelura, supported by additional medicines, licensing partnerships and clinical research.

- **Founded:** 1991
- **Headquarters:** Wilmington, United States
- **Founders:** Roy A. Whitfield (Co-founder; founding CEO), Randall W. Scott (Co-founder; founding chief scientific officer)
- **Products:** Jakafi (ruxolitinib), Jakafi XR (ruxolitinib extended release), Opzelura (ruxolitinib cream), Pemazyre (pemigatinib), Monjuvi / Minjuvi (tafasitamab)
- **Notable:** FDA approval of Jakafi for myelofibrosis in November 2011., Opzelura became the first FDA-approved treatment for repigmentation in vitiligo in July 2022., Niktimvo received initial FDA approval in August 2024.

## Products & services

- **Jakafi (ruxolitinib)** — Oral JAK1/JAK2 inhibitor with U.S. indications in specified patients with myelofibrosis, polycythemia vera and graft-versus-host disease; initial U.S. approval for myelofibrosis.
- **Jakafi XR (ruxolitinib extended release)** — Extended-release oral ruxolitinib approved in the U.S. in May 2026 for specified blood-disorder and GVHD indications.
- **Opzelura (ruxolitinib cream)** — Topical JAK1/JAK2 inhibitor initially approved in the U.S. for atopic dermatitis in 2021; nonsegmental vitiligo indication followed in 2022. Eligibility and safety requirements depend on local labeling.
- **Pemazyre (pemigatinib)** — FGFR inhibitor for specified molecularly defined bile-duct cancers and myeloid/lymphoid neoplasms; indications vary by territory.
- **Monjuvi / Minjuvi (tafasitamab)** — CD19-directed antibody used in specified relapsed or refractory lymphoma settings and combinations.
- **Zynyz (retifanlimab)** — PD-1 inhibitor with approved indications in Merkel cell carcinoma and squamous cell carcinoma of the anal canal, subject to local labeling.
- **Niktimvo (axatilimab-csfr)** — CSF-1R antibody approved for chronic GVHD after at least two prior systemic therapies in eligible patients; co-commercialized with Syndax in the U.S.
- **Iclusig (ponatinib), selected territories** — BCR-ABL inhibitor commercialized by Incyte in licensed territories including Europe for specified leukemias.
- **Atebrioz (zilurgisertib), licensed to Mirum** — Incyte-developed oral ALK2 inhibitor; FDA approved in September 2026 to reduce new heterotopic ossification volume in eligible FOP patients aged 12 and older.

## Achievements

- FDA approval of Jakafi for myelofibrosis in November 2011.
- Opzelura became the first FDA-approved treatment for repigmentation in vitiligo in July 2022.
- Niktimvo received initial FDA approval in August 2024.
- Total 2025 GAAP revenue reached $5.14 billion, up 21% from 2024.
- Jakafi XR received FDA approval in May 2026.

## Latest updates

- **2026-09** — Mirum and Incyte announced FDA approval of Atebrioz (zilurgisertib) for eligible FOP patients aged 12 and older.
- **2026-07** — Incyte reported Q2 GAAP revenue of $1.674 billion; Opzelura sales included a $246 million one-time non-cash benefit related to a CMS agreement.
- **2026-07** — Completed the Vega acquisition for $1.25 billion upfront, with up to $750 million in additional sales milestones; acquired investigational VGA039, now called latarcibart.
- **2026-05** — FDA approved Jakafi XR, an extended-release ruxolitinib formulation.

## Links

- Website: https://incyte.com
- LinkedIn: https://www.linkedin.com/company/incyte/
- Twitter/X: https://twitter.com/Incyte
- YouTube: https://www.youtube.com/channel/UCQu_9fYXOTWn4q3h-c0sKCg
- Instagram: https://www.instagram.com/incyte/
- Facebook: https://www.facebook.com/incyte/

---

Profile page: https://yespress.io/incyte
Published by YesPress — https://yespress.io
Last updated: 2026-10-22